COUNTERING COUNTERFEITS
COUNTERING COUNTERFEITS
Industry offers proposals to fight growing problem of fake drugs.
BAYER CHEMICALS TO TAKE A SPIN
BAYER CHEMICALS TO TAKE A SPIN
Split-off of chemicals will shift firm�s focus to life sciences
BIOTECH SCORES BIG THIRD-QUARTER GAINS
BIOTECH SCORES BIG THIRD-QUARTER GAINS
Substantial revenue and earnings growth continued unabated for yet another quarter
DRUG EARNINGS RALLY IN THE THIRD QUARTER
DRUG EARNINGS RALLY IN THE THIRD QUARTER
Major pharmaceutical firms see improvement in sales and earnings as the year progresses
It Lives for 29 Years?
It Lives for 29 Years?
A lawsuit filed April 11 in the U.S. District Court in Los Angeles has grabbed the attention of the life sciences community. The key parties are three high-profile biotech developers: MedImmune, Genentech and Celltech. MedImmune is challenging the validity and enforceability of an important Genentech patent. Behind that patent, MedImmune charges, is an illegal, anti-competitive agreement that ‘profoundly and fundamentally altered the competitive landscape in the biotechnology industry.’
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments